key: cord-0999151-7kd6yxh7 authors: Milanese, M.; Anselmo, M.; Buscaglia, S.; Garra, L.; Goretti, R.; Parodi, L.; Riccio, G.; Tassara, R.; Gnerre, P. title: COVID-19 after 6-months from hospital discharge: pulmonary function impairment and its heterogeneity date: 2021-06-18 journal: ERJ Open Res DOI: 10.1183/23120541.00196-2021 sha: a94dadc147243bc550d46c9869a44833ff0bbb8f doc_id: 999151 cord_uid: 7kd6yxh7 Until now, reports about pulmonary function in previously hospitalised subjects for COVID-19 are at discharge [1] or at 3–4 months [2–4]. The first study at 6 months is that of Huang et al. [5], enrolling 1733 discharged subjects, 349 of them underwent a pulmonary function study. COVID-19 after 6-months from hospital discharge: pulmonary function impairment and its heterogeneity. Milanese M, Anselmo M, Buscaglia S, Garra L, Goretti R, Parodi L, Riccio G, Tassara R, and Gnerre P on behalf of the ACOD Group To the Editor: Until now, reports about pulmonary function in previously hospitalized subjects for COVID-19 are at discharge (1) or at 3-4 months (2) (3) (4) . The first study at 6 months is that of Huang et al. (5) , enrolling 1733 discharged subjects, 349 of them underwent a pulmonary function study. We consecutively enrolled from 15 March to 15 June 2020, during the first pandemic wave in Italy, 135 discharged COVID-19 patients, aged ≤80 yrs, in a follow-up study (Assessment of Cardiac and pulmonary consequences in patients recOvered from coviD-19 infection, the ACOD study) approved by the regional ethics committee (CER Liguria), aiming to collect data at 6 and 12 months after discharge from Hospitals (Santa Corona, Santa Maria di Misericordia, San Paolo) serving an area of 280.000 habitants. The present research letter reports timely preliminary data on respiratory function at 6 months from discharge. Written informed consent was collected from any subject. Spirometry and pulmonary diffusion capacity test were performed following the American Thoracic Society/European Respiratory Society statements (6-7) with a Vyntus Body Plethysmograph (Vyaire Medical GmbH, Hoechberg, Germany). To minimise cross-infections, diffusing capacity of the lung for carbon monoxide (D LCO ) was measured by the single-breath method with Diffusion SB RT Module for Body Vyntus (Vyaire Medical, GmbH, Hoechberg, Germany). Abnormal data were that with a Z score >2SD (ULN, Upper Limit of Normality) by applying The Global Lung Function Initiative Network (GLI) reference values (8) (9) . Appropriate correction to D LCO for haemoglobin was considered (7) . Descriptive statistics are reported as mean (± standard deviation). Differences between two groups were analysed for statistical significance by Student's t-test (unpaired) and between more than two groups by ANOVA, Kruskal-Wallis, or χ 2 where appropriate. A two-sided p<0.05 was considered for all comparisons. Table I summarized demographic and pulmonary function characteristics of the 135 enrolled subjects at follow-up for moderate-to-severe COVID-19, subdivided by the treatment for their acute respiratory failure (PaO 2 <60 mmHg): 1) O 2 supplementation only, 2) Continuous Positive Airway Pressure (CPAP, by helmet), 3) invasive mechanical ventilation (MV). No differences were found between the 3 groups, apart from age and gender. At follow-up, impaired respiratory function was found 64 (47%) of the enrolled subjects, characterized by an older age (62±11 vs 55±10 yrs, p<0.001) and a higher mMRC dyspnea scale (1.58±0.76 vs 0.36±0.48, p<0.01), without any differences in the ratio Male/Female (44/20 vs 47/24) or in BMI index (28±5 vs 28±5, kg/m 2 ). In 46 (34%) subjects D LCO was impaired (61±14% of predicted), associated with reduced (62%) or normal (38%) or D LCO corrected for alveolar volume (K CO , 81±15% of predicted). Table II reports the pathophysiologic classification (10) of the impairment found: a) pulmonary restriction (Total Lung CapacityULN). No differences were found between groups on age, M/F ratio, BMI, mMRC score. K CO % of predicted was higher in the group with a restrictive pattern vs that with isolated D LCO reduction (p=0.04). At follow-up, D LCO reduction was mainly associated with pulmonary restriction (53%), as expected, and less frequently with airway obstruction/airway trapping (8%), but also isolated (38%). In the latter case, subjects did not report pulmonary thromboembolism during hospitalization or indirect signs of pulmonary hypertension at follow-up. When comparing our data with that of Huang et al. (5) , in moderate-to-severe COVID-19 (n=260), the impairment of respiratory function is similar among subjects requiring supplemental oxygen and less among those requiring CPAP or MV. Specifically, based on this subdivision, D LCO was impaired in 31 and 40% of subjects (vs 29 and 56%), pulmonary restriction was present in 14 and 26% of subjects (vs 10 and 35%), and FEV 1 /FVC